News

Aspen Neuroscience’s David Tastad, PhD, Presented at the Annual Society for Neuroscience Meeting

by
sfn1

Aspen Neuroscience’s David Tastad, PhD, presented the poster “Dopamine Neuron Regulation,” at the annual Society for Neuroscience (SFN) meeting on Sunday, November 13th. The presentation explored functional characterization of GBA1 mutations in iPSC-derived midbrain dopaminergic neurons.  “There was a great turnout at David’s poster at SFN 2022, a session packed with invigorating and collaborative discussions, … Read more

Aspen Neuroscience does not make determination on patient eligibility for clinical trials and all trial related enrollment and eligibility decisions are made by clinical trial sites under the direction of a Principal Investigator. ANPD001 is investigational and is not yet approved by the FDA. At this time, Aspen Neuroscience does not offer or participate in compassionate use or expanded access programs for ANPD001.

Aspen Neuroscience Pursues Autologous Cell Therapies for Parkinson’s with $147.5M Series B

by
Aspen Neuroscience Series B

The Scripps Research spinout eyes 2023 for dosing of its first patients with its first product, designed to treat idiopathic Parkinson’s disease.

Aspen Neuroscience does not make determination on patient eligibility for clinical trials and all trial related enrollment and eligibility decisions are made by clinical trial sites under the direction of a Principal Investigator. ANPD001 is investigational and is not yet approved by the FDA. At this time, Aspen Neuroscience does not offer or participate in compassionate use or expanded access programs for ANPD001.

Aspen Neuroscience collects large Series B to compete against Bayer’s Parkinson’s cell therapy

by

Damien McDevitt thinks frequently about the name Aspen Neuroscience. Specifically, should the neuroscience portion be dropped as the San Diego biotech considers expanding beyond the CNS?

Aspen Neuroscience does not make determination on patient eligibility for clinical trials and all trial related enrollment and eligibility decisions are made by clinical trial sites under the direction of a Principal Investigator. ANPD001 is investigational and is not yet approved by the FDA. At this time, Aspen Neuroscience does not offer or participate in compassionate use or expanded access programs for ANPD001.

An Autologous Stem Cell-Based Therapy for Parkinson’s Disease

by

Cell therapies hold great promise to treat Parkinson’s disease, but there’s an ongoing debate over how to best do this. One group—and I am firmly in this camp—maintains an autologous therapy, derived from a patient’s own cells, is the correct path. Others believe an allogeneic approach, using donor cells, would be more cost-effective.

Aspen Neuroscience does not make determination on patient eligibility for clinical trials and all trial related enrollment and eligibility decisions are made by clinical trial sites under the direction of a Principal Investigator. ANPD001 is investigational and is not yet approved by the FDA. At this time, Aspen Neuroscience does not offer or participate in compassionate use or expanded access programs for ANPD001.

Aspen Neuroscience Gets $70 Million Series A Funding Round

by

Aspen Neuroscience, a private biotech company developing the first autologous neuron replacement therapy to treat Parkinson’s disease, announced the close of its Series A funding round of $70 million. OrbiMed led the investment round with participation from ARCH Venture Partners, Frazier Healthcare Partners, Domain Associates, Section 32, and entrepreneur Sam Altman.

Aspen Neuroscience does not make determination on patient eligibility for clinical trials and all trial related enrollment and eligibility decisions are made by clinical trial sites under the direction of a Principal Investigator. ANPD001 is investigational and is not yet approved by the FDA. At this time, Aspen Neuroscience does not offer or participate in compassionate use or expanded access programs for ANPD001.

$70 Million Raised for Neuron Replacement Therapy Techniques to Treat Parkinson’s

by

Aspen Neuroscience has raised $70 million to advance the development of Parkinson’s disease therapies using patients’ own cells. The products, ANPD001 and ANPD002, are the first-ever Parkinson’s treatments designed to use a patient’s own cells as a replacement to restore neuronal function and to modify disease progression. This approach is referred to as an autologous … Read more

Aspen Neuroscience does not make determination on patient eligibility for clinical trials and all trial related enrollment and eligibility decisions are made by clinical trial sites under the direction of a Principal Investigator. ANPD001 is investigational and is not yet approved by the FDA. At this time, Aspen Neuroscience does not offer or participate in compassionate use or expanded access programs for ANPD001.

Possible Parkinson’s Stem Cell Treatment in San Diego, $6.5 Million and Loads of Media Coverage

by

A San Diego firm that has $22 million worth of financial roots in the California stem cell agency this month snagged a bonus — a ton of favorable attention for its efforts to treat Parkinson’s disease.  The fledgling business is Aspen Neuroscience, Inc., which was co-founded by Jeanne Loring, professor emeritus at the Scripps Research … Read more

Aspen Neuroscience does not make determination on patient eligibility for clinical trials and all trial related enrollment and eligibility decisions are made by clinical trial sites under the direction of a Principal Investigator. ANPD001 is investigational and is not yet approved by the FDA. At this time, Aspen Neuroscience does not offer or participate in compassionate use or expanded access programs for ANPD001.

Pioneering cell therapy for Parkinson’s disease gains funding boost

by

An autologous stem cell therapy for Parkinson’s disease (PD), with a potential to alter disease progression, received a boost when the programme received a seed funding totalling $6.5m from a group of venture capitalist firms. The funding is likely to help the company in advancing the programme to different stages of clinical development. 

Aspen Neuroscience does not make determination on patient eligibility for clinical trials and all trial related enrollment and eligibility decisions are made by clinical trial sites under the direction of a Principal Investigator. ANPD001 is investigational and is not yet approved by the FDA. At this time, Aspen Neuroscience does not offer or participate in compassionate use or expanded access programs for ANPD001.

How Research in Space Can Launch Girls’ Ideas

by

What if… …examining barley seeds in microgravity could help us grow food in space and improve crop growth back on the ground? …sending mice into orbit could teach us how to prevent human bone and muscle loss on Earth? …researching how cells grow in spaceflight could help patients on Earth living with Parkinson’s disease and … Read more

Aspen Neuroscience does not make determination on patient eligibility for clinical trials and all trial related enrollment and eligibility decisions are made by clinical trial sites under the direction of a Principal Investigator. ANPD001 is investigational and is not yet approved by the FDA. At this time, Aspen Neuroscience does not offer or participate in compassionate use or expanded access programs for ANPD001.

Jeanne Loring named ‘Stem Cell Pioneer of the Year’ in inaugural Xconomy Awards

by

Genomics researcher Jeanne Loring, PhD, professor emeritus at Scripps Research and founding director of the institute’s Center for Regenerative Medicine, was honored as “Stem Cell Pioneer of the Year” at the Xconomy Awards San Diego’s gala. The award is an acknowledgement of Loring’s groundbreaking work not only in academia but also as co-founder and chief … Read more

Aspen Neuroscience does not make determination on patient eligibility for clinical trials and all trial related enrollment and eligibility decisions are made by clinical trial sites under the direction of a Principal Investigator. ANPD001 is investigational and is not yet approved by the FDA. At this time, Aspen Neuroscience does not offer or participate in compassionate use or expanded access programs for ANPD001.

Aspen Neuroscience Logo

Aspen Neuroscience leverages stem cell biology and genomics to provide the world’s first autologous induced pluripotent stem cell (iPSC)-derived neuron replacement therapy for Parkinson's disease.

Contact

10835 Road to the Cure
Ste. 100
San Diego, CA 92121

© 2025 Aspen Neuroscience - All Rights Reserved